On 18 May 2018, WHO has issued a web statement signalling a potential risk of neural tube defects in infants born to women who were taking dolutegravir (DTG) at the time of conception.

The ICHQ3D guideline presents a process to assess and control elemental impurities in drug products using the principles of risk assessment.

In April 2018, EMA published a report with an overview of the activities of the programme between 2011 and 2016.

WHO Prequalification Team - Medicines (PQTm) added the below new product to its prequalified list: